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Azoles are antifungal drugs used to treat fungal infections such as candidiasis in humans. Their
extensive use has led to the emergence of drug resistance, complicating antifungal therapy for yeast
infections in critically ill patients. Combination therapy has become popular in clinical practice as a
potential strategy to fight resistant fungal isolates. Recently, amphiphilic tobramycin analogues,
C12 and C14, were shown to display antifungal activities. Herein, the antifungal synergy of C12 and
C14 with four azoles, fluconazole (FLC), itraconazole (ITC), posaconazole (POS), and voriconazole
(VOR), was examined against seven Candida albicans strains. All tested strains were synergistically
inhibited by C12 when combined with azoles, with the exception of C. albicans 64124 and MYA-2876
by FLC and VOR. Likewise, when combined with POS and ITC, C14 exhibited synergistic growth
inhibition of all C. albicans strains, except C. albicans MYA-2876 by ITC. The combinations of FLCC14 and VOR-C14 showed synergistic antifungal effect against three C. albicans and four C. albicans
strains, respectively. Finally, synergism between C12/C14 and POS were confirmed by time-kill and
disk diffusion assays. These results suggest the possibility of combining C12 or C14 with azoles to treat
invasive fungal infections at lower administration doses or with a higher efficiency.

Invasive fungal infections such as candidiasis have become a major cause of mortality and morbidity, especially among immunocompromised (HIV, cancers) and critically ill patients worldwide1,2. The
National Healthcare Safety Network (NHSN) at the Centers of Diseases Control and Prevention (CDC)
has reported that Candida spp. ranked the fifth among hospital-acquired pathogens3. Candida spp. have
also been reported as the fourth most common causative pathogens of nosocomial bloodstream infection
claiming more lives in the United States4.
Azoles, echinocandins, allylamines, and polyenes are the four major classes of antifungal agents that
are used to treat candidiasis as well as other type of fungal infections in humans. Among these four,
azoles such as fluconazole (FLC), itraconazole (ITC), posaconazole (POS), and voriconazole (VOR) are
considered first line drugs to treat refractory fungal diseases (Fig. 1)5. The fungistatic nature and prolonged use of azoles to treat fungal infections, however, has promoted the selection and emergence
of drug resistant fungal strains. This necessitates either the development of novel antifungal drugs or
improved therapeutic strategy to overcome drug resistance problems by C. albicans. In clinical settings,
combination therapy has become a potential alternative to treat invasive fungal infections by improving clinical efficacy of existing drugs such as azoles and reducing their side effects to host by lowering
administrative doses. Previously, promising results were observed by combining azoles with different
compounds such as tacrolimus (FK506)6, cyclosporine A7, amiodarone8, and retigeric acid B9 against C.
albicans strains.
We recently demonstrated that modifying the aminoglycoside tobramycin (TOB) at the 6”-position
by incorporating linear alkyl chains (C6–C22) in a thioether linkage resulted in chain-length-dependent
antibacterial and antifungal activities against various bacteria and fungi with resistance to the parent
drug, TOB, itself10,11. This was especially true for TOB derivatized with linear alkyl chains of 12 and 14
carbons in length (referred to as C12 and C14 from here on) (Fig. 1). However, synergistic interactions
between the amphiphilic aminoglycosides C12 and C14 and azoles against fungal strains have not yet been
explored. In this study, in an effort to establish if TOB derivatives could be used in combination with
Department of Pharmaceutical Sciences, University of Kentucky, Lexington, KY, 40536-0596, USA. Correspondence
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Figure 1. Structures of the 6”-thioether TOB analogues C12 and C14 and of the azole antifungal agents
used in this combination study.

currently available antifungal agents, we evaluated the combined effects of C12 and C14 with four azoles
against azole-sensitive and azole-resistant C. albicans by checkerboard, time-kill curve, and disk diffusion
assays. Additionally we have determined the in vitro cytotoxicity effect of TOB analogues and azoles in
combination against mammalian cells.

Results

In vitro antifungal activities of drugs alone. Prior to investigating the effect of combining C12 or
C14 with four azoles (FLC, ITC, POS, and VOR), the MIC values of these compounds were determined
individually against seven strains of C. albicans (Tables 1 and 2). The clinical sources and susceptibility/
resistance profile of these strains, as reported by the American Type Culture Collection (ATCC), are
presented in Table S1.
Based on complete inhibition (MIC-0) (Tables 1 and 2), C12 and C14 displayed MIC values of 16–32 μ g/mL
and 8 μ g/mL, respectively, against all C. albicans strains tested. These MIC values are consistent with
those previously reported for these compounds against these specific yeast strains11. When compared
to C12 and C14, FLC, ITC, POS, and VOR displayed higher MIC values against the majority of the yeast
strains tested (MIC values ranged from ≥ 25 μ g/mL, 12.5- > 25 μ g/mL, 10- > 20 μ g/mL, and ≥ 10 μ g/mL,
respectively), with the exception of the C. albicans ATCC 10231 (A) strain where ITC, POS, and VOR had
MIC values of 0.78 μ g/mL, 0.62 μ g/mL, and 0.31 μ g/mL, respectively. The MIC values of azoles against
yeast strains were determined based on 50% inhibition or MIC-0 and were consistent with previously
reported MICs for these compounds. However, due to the long trailing growth effects by azole susceptible
strains C. albicans MYA-2876 (C) and C. albicans MYA-2310 (E), we did observe higher MIC-2 values
for all azoles against these strains. To validate our MIC data of azoles against these two strains (C and
E), we also tested caspofungin as a control in the same set of MIC testing experiments. It is important
to note that ATCC has reported these two strains (C and E) as sensitive to caspofungin. Unlike azoles,
caspofungin showed complete inhibition at < 0.48 μ g/mL against these strains (Table S2).
In vitro synergistic antifungal activities. Having established the individual MIC values for C12,
C14, FLC, ITC, POS, and VOR, the MIC and FICI values of C12 and C14 in combination with the four
azoles (FLC, ITC, POS and VOR) were determined in checkerboard assays against the seven strains of
C. albicans (Tables 1 and 2). When combined with FLC or ITC or POS or VOR, C12 showed strong synergistic inhibitory effects against the majority of the C. albicans strains tested with FICI values ranging
from 0.07–0.5 (FLC or ITC or POS plus C12) and 0.07–0.27 (VOR plus C12). The only combinations
for which no synergistic effects were observed were FLC plus C12 (FICIs =  0.51 and 1) or VOR plus
C12 (FICIs =  0.62 and 0.75) against C. albicans ATCC 64124 (B) and C. albicans ATCC MYA-2876 (C),
respectively. Likewise, the combination of C14 with FLC or ITC or POS or VOR also exhibited good
synergy against the majority of the C. albicans strains tested, with FICI values ranging from 0.28–0.5
(FLC plus C14), 0.18-0.5 (ITC plus C14), 0.18-0.49 (POS plus C14), and 0.14–0.37 (VOR plus C14). With
C14, the combinations for which no synergistic effects were observed were FLC or VOR plus C14 against
C. albicans ATCC 10231 (A), C. albicans ATCC 64124 (B), and C. albicans ATCC MYA-2876 (C), as well
as FLC plus C14 (FICI =  1) against C. albicans ATCC MYA-1003 (G).
Time-kill studies of drug combinations. To confirm the synergistic inhibitory effects of C12 or C14
and POS against the azole-resistant C. albicans ATCC 64124 (B) strain, representative time-kill studies
Scientific Reports | 5:17070 | DOI: 10.1038/srep17070
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MICs of drugs (μ g/mL)
Alone
Drugs and Strainsa

In combination

Azole

C12

Azole

C12

FICIs

Interpretation

C. albicans 10231 (A)b

25

32

C. albicans 64124 (B)b

> 25

32

1.56

8

0.31

SYN

0.78

16

0.53

IND

C. albicans MYA-2876 (C)

> 25

C. albicans 90819 (D)b

> 25

16

12.5

8

1

IND

32

1.56

2

0.12

SYN

C. albicans MYA-2310 (E)c
b

> 25

16

0.39

1

0.07

SYN

C. albicans MYA-1237 (F)

> 25

32

1.56

2

0.12

SYN

C. albicans MYA-1003 (G)b

> 25

32

6.25

8

0.5

SYN

C. albicans 10231 (A)b

0.78

32

0.049

4

0.18

SYN

C. albicans 64124 (B)b

> 25

32

1.56

8

0.31

SYN
SYN

FLC

c

ITC

C. albicans MYA-2876 (C)

12.5

16

3.12

4

0.5

C. albicans 90819 (D)b

> 25

32

0.78

4

0.15

SYN

C. albicans MYA-2310 (E)c

12.5

16

0.39

2

0.15

SYN

C. albicans MYA-1237 (F)b

> 25

32

0.39

2

0.07

SYN

C. albicans MYA-1003 (G)b

> 25

32

0.39

4

0.15

SYN

C. albicans 10231 (A)b

0.62

32

0.15

8

0.5

SYN

C. albicans 64124 (B)b

> 20

32

1.25

2

0.12

SYN
SYN

c

POS

C. albicans MYA-2876 (C)

10

16

1.25

1

0.18

> 20

32

0.31

8

0.26

SYN

C. albicans MYA-2310 (E)c

10

16

0.62

1

0.12

SYN

C. albicans MYA-1237 (F)b

> 20

32

0.31

2

0.07

SYN

C. albicans MYA-1003 (G)b

> 20

32

1.25

2

0.12

SYN

C. albicans 10231 (A)b

0.31

32

0.07

8

0.27

SYN

C. albicans 64124 (B)b

> 10

32

1.25

16

0.62

IND

C. albicans MYA-2876 (C)

> 10

16

2.5

8

0.75

IND

C. albicans 90819 (D)b

> 10

32

0.15

4

0.14

SYN

C. albicans MYA-2310 (E)c

10

16

0.15

1

0.07

SYN

b

C. albicans MYA-1237 (F)

> 10

32

0.31

2

0.09

SYN

C. albicans MYA-1003 (G)b

> 10

32

0.31

4

0.14

SYN

c

C. albicans 90819 (D)b

VOR

c

Table 1. In vitro susceptibility of yeast strains to C12 and azoles alone and in combination. aAll of the
strains are from ATCC. bIndicates strains that are resistant to FLC, ITC, and VOR according to ATCC.
c
Indicates strains that are susceptible to FLC, ITC, and VOR according to ATCC. Note: SYN indicates
synergy (FICI ≤ 0.5) whereas IND indicates indifferent (FICI > 0.5–4).

were performed (Fig. 2). At 8 or 4 μ g/mL, C12 or C14 alone did not show inhibition to the growth of C.
albicans ATCC 64124 (B). In contrast, POS, at 10 μ g/mL, showed inhibition for the first 3 h of growth of
the yeast strain, and after that the growth was similar to that of the growth control (no drug). However,
the combined administration of C12 (2 μ g/mL) with POS (1.25 μ g/mL) and C14 (2 μ g/mL) with POS (1.25
or 2.5 μ g/mL) against C. albicans ATCC 64124 (B) yielded a ≥ 2 log10 decrease in CFU/mL after 9 h and
12 h of treatment compared with each compound alone, respectively (Fig. 2). The results obtained by
time-kill studies are consistent with those from the checkerboard assays.

Disk diffusion assays. To examine the nature of the drug interactions between C14 with POS or ITC
against the azole-resistant C. albicans ATCC 64124 (B) strain, disk diffusion assays were performed in
duplicate. C14 (500 or 700 μ g/mL), POS (100 μ g/mL), and ITC (150 μ g/mL) alone, when applied on disk,
did not show a zone of inhibition against C. albicans ATCC 64124 (B). However, when co-spotted, C14
Scientific Reports | 5:17070 | DOI: 10.1038/srep17070
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(500 μ g/mL) and POS (100 μ g/mL) or C14 (700 μ g/mL) and ITC (150 μ g/mL) resulted in a visible zone
of inhibition against this strain, which confirmed the synergistic antifungal interactions of these compounds (Fig. 3).

Cytotoxic effect of drug combinations. To investigate the cytotoxic effects of C12 or C14 and POS
alone and in combinations, assays were performed against A549 and BEAS-2B cells (Fig. 4 and Tables
S3-S6). As we previously reported11, C12 or C14, at their respective highest antifungal MIC values of 32 μ g/mL
and 8 μ g/mL, basically did not show toxicity against the A549 and BEAS-2B cell lines. On the other hand,
the newly tested POS at 20 μ g/mL, which is a concentration below its antifungal MIC value against C.
albicans ATCC 64124 (B), exhibited severe toxicity against the A549 and BEAS-2B cell lines, resulting in
≤ 37% cell survival in both cases. On a very positive note, when tested at 8-fold higher concentrations of
POS (10 μ g/mL) plus C12 or C14 (16 or 8 μ g/mL) in combinations than their synergistic antifungal MIC
values (Note: the synergistic MIC values for POS and C12, or C14 in combinations are 1.25 and 2 or 1),
only minimal or no toxicity were observed against the A549 and BEAS-2B cell lines, resulting in ≥ 47%
cell survival in both cases.

Discussion

Opportunistic fungal infections have become a serious threat to human health due to the rising population of immunocompromised patients as result of HIV infections, chemotherapy, and organ transplant12.
Azoles are drugs of choice for antifungal therapy for various fungal infections in humans, including candidiasis. However drug-drug interactions, severe side effects, and development of resistance have limited
their therapeutic efficacies against fungi13. Thus, new strategies are warranted to overcome antifungal
drug resistance and side effects due to use of high doses of these drugs.
In this study, we investigated the in vitro antifungal synergy of two amphiphilic TOB derivatives, C12
and C14, with four azoles (FLC, ITC, POS and VOR) against seven azole-resistant and azole-sensitive
strains of C. albicans. Our results demonstrated that C12 and C14 exhibit potent antifungal synergy in vitro
with all four azoles against the majority of the C. albicans strains tested. Despite displaying less antifungal
activity when used alone, C12 alone (16–32 μ g/mL) compared to C14 alone (8 μ g/mL), C12 demonstrated
better synergistic inhibitory effects when combined with azoles against all strains of C. albicans tested
with FICI values ranging from 0.07–0.5. The only combinations for which no synergy was detected were
those of C12 and FLC or VOR against C. albicans ATCC 64124 (B) and C. albicans ATCC MYA-2876
(C) (Table 1). Similarly, C14 also did not display synergy when used in combination with FLC and VOR
against these strains. Although C14 also displayed good antifungal synergy in combinations with all
azoles against the majority of the fungal strains tested (FICI values ranging from 0.14–0.5), more combinations yielded no synergy. In addition to the C14 with FLC or VOR against strains B and C, indifference
was observed with the combinations of FLC or VOR with C14 against C. albicans ATCC 10231 (A), FLC
with C14 against C. albicans ATCC MYA-1003 (G), as well as ITC with C14 against C. albicans ATCC
MYA-2876 (C) (Table 2). It is also noteworthy to mention that the MIC values of all azoles were greatly
reduced in presence of C12 or C14 against various fungal strains. For example, the MIC values of POS
were reduced by 64-fold against C. albicans ATCC 90819 (D) in the presence of C12 or C14. Also, POS
lowered the MIC values of C12 or C14 by 4-fold against same strain in both case. Alternative methods,
such as time-kill studies and disk diffusion assays, were also performed to evaluate the drug interactions
of C12 and C14 with POS or ITC (used for disk diffusion assays only) against C. albicans ATCC 64124 (B).
The results obtained further confirmed the synergistic interactions of C12 and C14 with POS and were in
agreement with the results obtained by checkerboard analysis against specific yeast strains. Interestingly,
although we did observe zones of inhibition for C12 and C14 with POS or ITC against C. albicans ATCC
64124 (B) in our disk diffusion assay, these were small. Probably, the higher molecular weight of TOB
analogues may have contributed the poor diffusion of these compounds through agar14 or interaction
of these polycationic compounds with sulfates and acids of agar polymer may have resulted reduced
inhibition with minor zone of inhibition15. Interestingly, when tested with antifungals other than azoles
such as caspofungin (an echinocandin) and naftifine (an allylamine), C12 and C14 did not show synergy,
at least against one strain of C. albicans, C. albicans ATCC 64124 (B) (data not shown).
In this study, we included clinical isolates of C. albicans strains that are reported as azole (FLC,
ITC and VOR) resistant strains, except for two strains, C. albicans ATCC MYA-2876 (C) and C. albicans ATCC MYA-2310 (E), which are reported as azole-sensitive. In the majority of cases, C12 and C14
exhibited synergistic inhibitory effects with azoles against these strains. These observations indicates
that combination therapy using C12 or C14 with an azole may provide a new strategy to fight fungal
infections caused by resistant strains like C. albicans ATCC 64124 (B) that has mutations in its ERG11
sequences16,17.
Having established the synergistic antifungal interactions of C12 and C14 with azoles, and knowing
their non-cytotoxicity effects against A549 and BEAS-2B mammalian cell lines11, we further evaluated
the cytotoxicity effects of C12 and C14 in combination with POS against the A549 and BEAS-2B cell lines.
At above 8-fold higher than or equal to their synergistic antifungal MIC values, C12 and C14 with POS
exhibited minimal to no toxicity against these cell lines resulting in ≤ 47% cell survival (Fig. 4 and Tables
S3-S6). These results may suggest that the clinical efficacies of azoles can be resumed by achieving low
Scientific Reports | 5:17070 | DOI: 10.1038/srep17070
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MICs of drugs (μ g/mL)
Alone
Drugs and Strainsa

In combination

Azole

C14

Azole

C14

FICIs

Interpretation

C. albicans 10231 (A)b

25

8

6.25

4

0.75

IND

C. albicans 64124 (B)b

> 25

8

1.56

4

0.56

IND

C. albicans MYA-2876 (C)

> 25

8

12.5

4

1

IND

C. albicans 90819 (D)b

> 25

8

6.25

2

0.5

SYN

C. albicans MYA-2310 (E)c

> 25

8

6.25

2

0.5

SYN

b

C. albicans MYA-1237 (F)

> 25

8

0.78

2

0.28

SYN

C. albicans MYA-1003 (G)b

> 25

8

12.5

4

1

IND

C. albicans 10231 (A)b

0.78

8

0.19

2

0.5

SYN

C. albicans 64124 (B)b

> 25

8

0.78

2

0.28

SYN

12.5

8

1.56

4

0.62

IND

25

8

0.39

2

0.26

SYN

C. albicans MYA-2310 (E)c

12.5

8

0.78

1

0.18

SYN

b

C. albicans MYA-1237 (F)

> 25

8

3.12

1

0.25

SYN

C. albicans MYA-1003 (G)b

> 25

8

0.78

2

0.28

SYN

C. albicans 10231 (A)b

0.62

8

0.15

2

0.49

SYN

C. albicans 64124 (B)b

> 20

8

1.25

1

0.18

SYN
SYN

FLC

c

ITC

C. albicans MYA-2876 (C)

c

C. albicans 90819 (D)b

POS

C. albicans MYA-2876 (C)

10

8

1.25

2

0.37

> 20

8

0.31

2

0.26

SYN

C. albicans MYA-2310 (E)c

10

8

0.31

2

0.28

SYN

C. albicans MYA-1237 (F)b

> 20

8

1.25

1

0.18

SYN

C. albicans MYA-1003 (G)b

> 20

8

1.25

2

0.31

SYN

C. albicans 10231 (A)b

0.31

8

0.03

4

0.59

IND

C. albicans 64124 (B)b

> 10

8

5

4

1

IND

c

C. albicans 90819 (D)b

VOR

C. albicans MYA-2876 (C)

10

8

5

2

0.75

IND

> 10

8

0.31

1

0.15

SYN

C. albicans MYA-2310 (E)c

10

8

0.15

1

0.14

SYN

b

C. albicans MYA-1237 (F)

> 10

8

0.31

1

0.15

SYN

C. albicans MYA-1003 (G)b

> 10

8

2.5

1

0.37

SYN

c

C. albicans 90819 (D)b

Table 2. In vitro susceptibility of yeast strains to C14 and azoles alone and in combination. aAll of the
strains are from ATCC. bIndicates strains that are resistant to FLC, ITC, and VOR according to ATCC.
c
Indicates strains that are susceptible to FLC, ITC, and VOR according to ATCC. Note: SYN indicates
synergy (FICI ≤ 0.5) whereas IND indicates indifferent (FICI > 0.5–4).

doses with less toxicity when combined with C12 or C14 to treat stubborn mycoses. Besides, the results
may provide flexibility to extrapolate the range of concentrations that can be used in combination to
perform in vivo experiments.
Certain amphiphilic aminoglycosides such as FG08 and K20 were reported to inhibit fungi by disrupting fungal membrane18–20. Recently, we reported that C12 and C14 inhibit fungi by inducing apoptosis leading to fungal membrane disruption11. On the other hand, azoles kill fungi by inhibiting the
cytochrome P450-dependent enzyme sterol 14-α -demethylase involved in ergosterol biosynthesis. The
mechanism by which C12 and C14 synergize with azoles remains to be established in studies that are
out of scope for this manuscript. One of the major mechanism of resistance to azoles by fungi is due
to up-regulation of efflux pumps (CDR1 and CDR2) that lower the intracellular drug concentrations21.
When azoles are combined with C12 and C14, it could be expected that C12 and C14 could enhance
azoles permeability to fungi by altering fungal membrane integrity that may intensify the fungal killing.
However, the cascades of multiple secondary effects such as reactive oxygen species (ROS) accumulation,
Scientific Reports | 5:17070 | DOI: 10.1038/srep17070
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Figure 2. Representative time-kill studies of 6”-thioether TOB analogues C12 (panel A) or C14
(panel B) with POS alone and in combination against azole-resistant C. albicans ATCC 64124 (strain B).
(A) Cultures were exposed to C12 at 8 μ g/mL (black inverted triangle), POS at 10 μ g/mL (white circle), the
combination of C12 at 2 μ g/mL and POS at 2.5 μ g/mL (white triangle), and no drug (control, black circle).
(B) Cultures were exposed to C14 at 4 μ g/mL (black inverted triangle), POS at 10 μ g/mL (white circle), and
the combination of C14 at 2 μ g/mL and POS at 1.25 μ g/mL (white triangle) or C14 at 2 μ g/mL and POS at
2.5 μ g/mL (black square), and no drug (control, black circle). Note: inset in panels (A,B) After 24 h of no
drug/drug exposure, cultures of C. albicans ATCC 64124 (strain B) were further treated with Alamar Blue
dye (25 μ g/mL) and incubated at room temperature in the dark for another 10 h. Culture tubes showing red
indicates cell survival whereas blue indicates cell death. Lanes a and f =  sterility control; b and g =  growth
control; c and h =  POS (10 μ g/mL); d, i, and j =  POS + AG derivative (concentrations are POS (2.5 μ g/mL)
+ C12 (2 μ g/mL) or POS (1.25 μ g/mL) + C14 (2 μ g/mL) or POS (2.5 μ g/mL) + C14 (2 μ g/mL)); e and k =  AG
derivative alone (C12 (8 μ g/mL) or C14 (4 μ g/mL)).

mitochondrial membrane potential dissipation, and DNA condensation and fragmentation as a result of
membrane disruption action cannot be overlooked as a cause of death22.

Conclusions

In conclusion, our study demonstrated the synergistic combination effects between C12 or C14 and four
azoles against the majority of the C. albicans strains tested. These synergistic interactions were further
confirmed by time-kill curves and disk diffusion assays. The combination effects of C12 or C14 and azoles
appears non toxic to mammalian cells at higher or equal to synergistic antifungal MIC values of these
drugs against fungi. C12 or C14-azoles combination therapy might be mainly beneficial to treat invasive
fungal infections like candidiasis. Future studies in our laboratory will be focused on establishing the
mechanism of action of these drugs in combination.

Scientific Reports | 5:17070 | DOI: 10.1038/srep17070
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Figure 3. Disk diffusion assay (done in duplicate; series 1 and 2) showing that C14, when used
in combination with the azoles POS or ITC, kills C. albicans ATCC 64124 (strain B). Note: at the
concentrations tested, C14, POS, or ITC do not kill the fungal strain. a1 and a2 =  POS (100 μ g) + C14
(500 μ g); b1 and b2 =  POS (100 μ g); c1 and c2 =  C14 (500 μ g); d1 and d2 =  H2O; e1 and e2 =  ITC (150 μ g)
+ C14 (700 μ g); f1 and f2 =  ITC (150 μ g); g1 and g2 =  C14 (700 μ g); h =  H2O.

Materials and Methods

Materials. Tobramycin (TOB) was purchased from AK scientific (Union City, CA). All other chem-

icals were purchased from Sigma Aldrich (St. Louis, MO) and used without further purification. TOB
analogues with linear alkyl chains C12 and C14 were synthesized as described previously10 and were dissolved in double distilled water (ddH2O) at a final concentration of 10 g/L for storage at − 20 °C.

Antifungal agents. The antifungal agents fluconazole (FLC), itraconazole (ITC), posaconazole (POS),
and voriconazole (VOR) were obtained from AK Scientific, Inc. (Mountain View, CA). FLC, ITC, POS,
and VOR were dissolved in DMSO at a final concentration of 5 g/L. All of these solutions were stored
at − 20 °C.
Fungal strains and culture conditions. The yeast strains C. albicans ATCC 10231 (A), C. albicans
ATCC 64124 (B), and C. albicans ATCC MYA-2876 (C) were kindly provided by Dr. Jon Y. Takemoto
(Utah State University, Logan, UT, USA). The yeast strains C. albicans ATCC 90819 (D), C. albicans
ATCC MYA-2310 (E), C. albicans ATCC MYA-1237 (F), and C. albicans ATCC MYA-1003 (G) were
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Figure 4. Cytotoxicity of 6”-thioether C12 or C14 TOB analogues and POS alone and in combination
against mammalian cells. (A,C) A549 cells and (B,D) BEAS-2B cells were treated with C12 or C14, and POS
alone and in combinations at various concentrations and incubated at 37 °C for 24 h in a CO2 incubator.

purchased from the ATCC (Manassas, VA, USA). All yeast strains were cultivated at 35 °C in RPMI
1640 medium.
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In vitro antifungal activities. Based on the previously reported MIC values for C12, C14, FLC, ITC,
POS11, appropriate ranges of concentrations for in vitro drug combination studies were determined. It
is important to note that the MIC values for C12, C14, FLC, ITC, POS alone were again determined here
to allow for direct comparison with combination results. In the current study, MIC values for C12, C14,
FLC, ITC, POS, and VOR against different fungal strains were determined as described in the CLSI
document M27-A323 with minor modifications. Some of our fungal strains, such as C. albicans ATCC
64124 (strain B), tend to produce pseudohyphae (filaments) in RPMI 1640 medium, which has been
found to compromise cell counting when using a hemocytometer. Therefore, we used potato dextrose
broth (PDB) to prepare yeast inocula and later diluted in RPMI 1640 medium to perform MIC value
determination, as well as checkerboard and time-kill assays. Modifications included growing yeast cells
in potato dextrose broth (PDB) for 24–48 h at 35 °C, diluting the yeast culture in RPMI 1640 medium to
a concentration of 1 ×  106 cells/mL (as determined by using an hemocytometer) and using a final inoculum size of 5 ×  104 cfu/mL for all the assays (Note: identical results were obtained when using 5 ×  103
cfu/mL and 5 ×  104 cfu/mL as a final inoculum size when tested against strain B. As it is known that a
higher inoculum size of cells can raise the MIC values determined, we selected 5 ×  104 cfu/mL to provide
conditions that would lead to the highest MIC values possible for our compounds so that we could really
determined their potential). Two-fold serial dilution of C12, C14, FLC, ITC, POS, and VOR was prepared
using RPMI 1640 medium (100 μ L) and cell suspension (100 μ L) was added to 96-well microtiter plate to
achieve final drug and inoculum concentration of 0.15–10 mg/L and 5 ×  104 cfu/mL, respectively. Plates
were incubated for 48 h at 35 °C. The MIC values for all azoles studied were defined as the lowest drug
concentration that inhibits 50% of fungal cell growth or MIC-2. The MIC values for C12 and C14 were
defined as the lowest drug concentration that yielded complete growth inhibition or MIC-0.
Determination of percentage of yeast cell growth inhibition used to determine MIC-2 values
for FLC, ITC, POS, VOR, and caspofungin. To confirm the susceptibility profile of yeast strains C

and E, we determined the percentage of C. albicans ATCC MYA-2876 (C) and C. albicans ATCC MYA
2310 (E) growth inhibition by FLC, ITC, POS, VOR, and caspofungin. The experiments were performed
as described above for the in vitro antifungal activities and percentages of growth at concentrations varying from 0.48-31.25 μ g/mL of azoles or caspofungin were measured by reading absorbance at 600 nm
(A600) using a SpectraMax M5 plate reader.

Antifungal checkerboard analysis. The synergistic interaction between C12 and C14 with four azoles

(FLC, ITC, POS, and VOR) was evaluated against various strains of C. albicans using a microdilution
checkerboard assay according to CLSI M27-A323. The test was performed in 96-well plates using RPMI
1640 medium. It is important to note that the MIC values were also determined for all azoles and TOB
analogues alone in the same set of experiments in checkerboard assays for comparision. These MIC
values are not from previous reports. The final concentration of yeast cells used was 1 ×  104 cfu/mL
as verified by colony counting. The final concentration of drugs ranged from 0.25–32 μ g/mL for C12,
0.06–8 μ g/mL for C14, 0.39–25 μ g/mL for FLC, 0.39–25 μ g/mL for ITC, 0.31–20 μ g/mL for POS, and
0.31–10 μ g/mL for VOR. Plates were incubated for 48 h at 35 °C. Each test was performed in duplicate.
A non-parametric model based on Loewe Additivity (LA) theory was used to analyze the nature of
in vitro interaction of C12 and C14, and all four azoles using fractional inhibitory concentration index
(FICI)24. According to LA theory, FICI can be defined as the sum of the ratios of the MIC values of
each drug when used in combination to their respective MIC values when used alone. Drug interactions
were classified as synergistic (SYN), indifferent (IND), or antagonistic (ANT) according to the fractional
inhibitory concentration index (FICI). The interaction was defined as synergistic if the FICI was ≤ 0.5,
indifferent if > 0.5–4, and antagonistic if > 4.

Time-kill studies of drug combinations. Representative time-kill studies were performed to inves-

tigate the activity of C12 and C14 in the presence or absence of POS against one azole-resistant strain,
C. albicans ATCC 64124 (B). These assays were performed in 15 mL culture tubes using RPMI 1640
medium as previously described25. Different sets of cell suspensions were prepared with C12 (8 μ g/mL),
C14 (4 μ g/mL), and POS alone (10 μ g/mL), or combinations of C12 (2 μ g/mL) plus POS (2.5 μ g/mL) or
C14 (2 μ g/mL) plus POS (1.25 and 2.5 μ g/mL), or growth control (no drug) and sterility control (no cells
and no drug). The final inoculum size of yeast cells used was 105 cfu/mL as confirmed by colony count.
The cell suspensions were then incubated at 35 °C with constant shaking (200 rpm). Aliquot of 100 μ L
from each tubes were removed at 0, 3, 6, 9, 12, and 24 h, and serially diluted in sterile ddH2O. 50 μ L of
each dilution was plated onto potato dextrose agar (PDA) and then incubated at 35 °C. Colony counts
were determined after 48 h of incubation. The experiments were performed in duplicate.

Disk diffusion assays. The disk diffusion assays were performed in duplicate according to the CLSI
document M44-A226. C. albicans ATCC 64124 (B), at a density of ~5 ×  105 cfu/mL, were spread onto PDA
plates. Sterile filter disks (~0.6 cm) were placed on the agar surface. 10 μ L aliquot of POS (100 μ g/mL),
ITC (150 μ g/mL), and C14 alone (either 500 or 700 μ g/mL), or combinations of C14 (500 μ g/mL) plus POS
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(100 μ g/mL) or C14 (700 μ g/mL) plus ITC (150 μ g/mL) were loaded onto the disks and then incubated
at 35 °C for 48 h before analysis.

Cytotoxic effect of drug combinations. Cytotoxicity assays were performed as previously
described27 with minor modifications. The human lung carcinoma epithelial cells A549 and the normal
human bronchial epithelial cells BEAS-2B were grown in DMEM containing 10% fetal bovine serum
(FBS) and 1% antibiotics. The confluent cells were then trypsinized with 0.05%-trypsin-0.53 mM EDTA
and resuspended in fresh medium (DMEM). The cells were transferred into 96-well microtiter plates at
a density of 3000 cells/well and were grown overnight. The following day, checkerboard plates were prepared to evaluate the cytotoxic effects of POS, and C12 or C14 alone and in combination against A549 and
BEAS-2B cells. The checkerboard plates were prepared in a new 96-well microtiter plates as described
above in antifungal checkerboard analysis except that drugs were diluted in DMEM medium in a final
volume of 200 μ L. The final concentration of drugs ranged from 0.25–32 μ g/mL for C12, 0.06-8 μ g/mL
for C14, and 0.31–20 μ g/mL for POS. The media containing cells were then replaced by 200 μ L of fresh
culture media containing drugs either alone or in combinations from the checkerboard plates. The cells
were incubated for additional 24 h at 37 °C with 5% CO2 in a humidified incubator. To evaluate cell
survival, each well was treated with 10 μ L (25 mg/L) of resazurin sodium salt (Sigma-Aldrich) for 3–6 h.
Metabolically active cells can convert the blue non-fluorescent dye resazurin to the pink and highly
fluorescent dye resorufin, which can be detected at A560 excitation and A590 emission wavelengths by
using a SpectraMax M5 plate reader. Triton X-100 (1%, v/v) gave complete loss of cell viability and was
used as the positive control. Percent cell survival was calculated as: (control value – test value)× 100/
control value, where control value represents cells + resazurin – drug, and test value represents cells +
resazurin + drug.

®
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